Data

While Future4care does not host data, we do facilitate connections between the startups we accelerate and our founders or partners who can share data. Below you will find the eligible data presented in the form of a metadata catalog.

Please note that access to this data will not be automatic and will be done on a case-by-case basis, following the review of a protocolized explanation on the processing and use of the data. The access to the data will be organized through a contract between the two stakeholders and will then take place within the secure platform of the founder or partner.

Topic Company/Data owner Type of data Key contact DB Name Description Service legal agreement for data accessibility Population of interest Data format File format Data size Descriptive stats Context of the data creation Start date End date Last update
BUSINESS PROVIDER GENERALI Company data.f4c@generali.com APPORTEURS Business provider (entities directly in contact with the client) * GENERALI network Structured HDFS 20 Mo 3 kind of business providers, 500 agencies NA 2010 2021 2021
CLIENTS GENERALI Client data.f4c@generali.com CLIENTS Generali insured persons * GENERALI clients Structured HDFS 1 Go 500K clients NA 2010 2021 2021
CONTRACTS GENERALI Client data.f4c@generali.com CONTRATS Contracts (Individual / Collective / Pension) * GENERALI contracts Structured HDFS 300 Mo 1M contracts NA 2010 2021 2021
CONTRACTS - BENEFICIARIES GENERALI Client data.f4c@generali.com CONTRATS - BENEFICIAIRES Contracts beneficiaries * GENERALI contracts Structured HDFS 150 Mo 1M beneficiaries NA 2010 2021 2021
HEALTH CARE BENEFITS GENERALI Health data.f4c@generali.com PRESTATIONS_SANTE Health care benefits used by insured persons * GENERALI benefits Structured HDFS 100 Go 2 billions procedures NA 2010 2021 2021
PENSION BENEFITS GENERALI Health data.f4c@generali.com PRESTATIONS_PREV Pension benefits used by insured persons * GENERALI benefits Structured HDFS 20 Go 100M NA 2010 2021 2021
HEALTH CARE BENEFITS - PROCEDURES GENERALI Health data.f4c@generali.com PRESTATIONS - ACTES Data repository for health care benefits procedure * GENERALI benefits Structured HDFS < 1 Mo 500 procedures NA 2010 2021 2021
PHYSICAL INJURIES GENERALI Health data.f4c@generali.com SINISTRES_CORPO Prejudice for physical injuries * GENERALI benefits Structured HDFS 1 Go 1M lines NA 2010 2021 2021
CARE PROVIDER GENERALI Care provider data.f4c@generali.com PRESTATAIRES Care provider (prescriber and executing) * CARE PROVIDER Structured HDFS NA NA NA 2010 2021 2021
Health Insurance Orange Client fluxvision.support@orange.com Transport Mobility and frequentation indicators ** People in France Strutured csv > 1 Go Number of trips per day between two zones of the metropolitan territory (predefined zones) - The origin and destination are defined by an immobility of 1H or 3H on the zones. - On two independent areas: - Macro: Departments and subdivisions of departments in metropolitan France (117 zones). - Micro: predefined zones with grouping of communes (1 400 zones). - The O/D flows are distributed by : - French/foreigners (according to the nationality of the mobile operator) - Age groups for the French (7 categories) - Time of arrival at destination, by 2h slots (from 7h to 1h) then 1 time step on the 1h-7h range. - Values between 0 and 20 are replaced by #. Macro : Departements and subdivisions of departements France metropolitan (117 zones). Micro : Predefined zones with grouping of communes (1 400 zones). January 2019 2021 2021
Health Insurance Orange Client fluxvision.support@orange.com Tourism Mobility and frequentation indicators ** People in France Strutured csv > 1 Go Aggregated key indicators, with an average trend, for a macroscopic knowledge of the territory. - Average attendance volume, by day type in the Study Area between 06:00 and 00:00. - Profile of French visitors (only for attendance) - CSP profile (Orange Geolife segmentation). - Distribution by age group. - Distribution of men and women. - Location of overnight stays / day before (EPCI throughout France) - Number of stays and length of stay of tourists, monthly average France/international. - International/departmental origin. - French visitors per department of residence - International visitors by country or group of countries 96 departements of France Metropolitan July 2019 2021 2021
Health Insurance Orange Client fluxvision.support@orange.com Retail Mobility and frequentation indicators ** People in France Strutured csv > 1 Go Indicators reported as a monthly average - According to 3 profile of day type : - Business day - Saturday - Sunday - Segmented : - Local / International (According to SIM card references) - Duration of presence (daily indicators): <30mn'; 30mn' - 3h; > 3h Attendance Indicators: - Unique attendance per day - Attendance by 30 min slots Mobility indicators - Daytime activity zone - Overnight zone Socio-demographic profile indicators - Geographic origin - Age, gender, CSP (Category Social Professional) Predefined zones based on the INSEE IRIS zones, 222 Cœur de Ville and the 210 largest municipalities in France. September 2019 2021 2021
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years *** Influenza infection; Influenza, Human Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/QID01_Report_Summary.pdf oct-12 oct-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years *** Influenza infection; Influenza, Human Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL http://www.clinicaltrials.gov/ct2/show/study/NCT01712984?term=QID01&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years *** Influenza infection; Influenza, Human Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc11628_summary_V2.pdf déc-11 sept-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://www.clinicaltrials.gov/ct2/show/NCT01499082?term=EFC11628&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc11628_summary_V2.pdf
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination with Oral Antihyperglycemic Drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc11629_summary.pdf déc-11 nov-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination with Oral Antihyperglycemic Drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://www.clinicaltrials.gov/ct2/show/study/NCT01499095?term=EFC11629&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination with Oral Antihyperglycemic Drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023770-39
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy *** Thromboprophylaxis Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-s/ juin-08 nov-10
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy *** Thromboprophylaxis Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00694382?term=NCT00694382&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy *** Thromboprophylaxis Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007943-29
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer *** Colonic Neoplasms Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-o/ oct-98 avr-03
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer *** Colonic Neoplasms Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00275210?term=00275210&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer *** Colonic Neoplasms Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 16-week, randomized, open-label, controlled study comparing the efficacy and safety of a new formulation of insulin glargine versus Lantus in patients with type 1 diabetes mellitus *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/pdy12777-summary.pdf août-12 mai-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 16-week, randomized, open-label, controlled study comparing the efficacy and safety of a new formulation of insulin glargine versus Lantus in patients with type 1 diabetes mellitus *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://www.clinicaltrials.gov/ct2/show/study/NCT01658579?term=PDY12777&rank=1&sect=X01256
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 16-week, randomized, open-label, controlled study comparing the efficacy and safety of a new formulation of insulin glargine versus Lantus in patients with type 1 diabetes mellitus *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin / GetGoal Duo1 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/ oct-09 août-11
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin / GetGoal Duo1 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00975286?term=NCT00975286&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin / GetGoal Duo1 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007335-40
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/ févr-12 mai-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01517412?term=NCT01517412&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002416-85
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin / GetGoal Duo-2 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc12626_summary.pdf janv-13 déc-14
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin / GetGoal Duo-2 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01768559?term=NCT01768559&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin / GetGoal Duo-2 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004096-38
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period / GetGoal-M-Asia *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/EFC1132_summary.pdf juil-10 déc-11
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period / GetGoal-M-Asia *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01169779?term=NCT01169779&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period / GetGoal-M-Asia *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/ juin-10 févr-15
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01147250?term=NCT01147250&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012852-26
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs Not available janv-07 30-déc-20
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00418886?term=00418886&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003695-35
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs With a 6-month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc12347_summary.pdf 30-déc-20 11-sept-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs With a 6-month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01676220?term=efc12347&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs With a 6-month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=EFC12347
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc12456_summary.pdf sept-12 mars-14
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01683266?term=efc12456&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=efc12456
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen *** Prostatic Neoplasm, Prostate Cancer Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-c/ janv-07 sept-09
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen *** Prostatic Neoplasm, Prostate Cancer Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00417079?term=00417079&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen *** Prostatic Neoplasm, Prostate Cancer Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen *** Prostatic Neoplasm, Prostate Cancer Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-c/ avr-11 août-15
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen *** Prostatic Neoplasm, Prostate Cancer Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01308580?term=01308580&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen *** Prostatic Neoplasm, Prostate Cancer Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022163-35
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc12512_summary.pdf sept-12 juin-14
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01689142?term=NCT%23+01689142&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/efc12449_summary.pdf sept-12 avr-14
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01689129?term=efc12449&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period *** Diabetes Mellitus Type 1 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-a/ déc-02 janv-10
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00050778?term=CAMMS223&draw=1&rank=2
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-a/ août-07 avr-11
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00530348?term=camms323&rank=2
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001161-14
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-a/ oct-07 sept-11
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00548405?term=camms324&rank=2
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy *** Multiple Sclerosis Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001162-32
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A prospective, longitudinal, non-pharmacological, case-controlled study to evaluate longitudinal disease behavior and biomarker data over a 52-week period in idiopathic pulmonary fibrosis patients *** Idiopathic Pulmonary Fibrosis Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs Not available N/A N/A
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A prospective, longitudinal, non-pharmacological, case-controlled study to evaluate longitudinal disease behavior and biomarker data over a 52-week period in idiopathic pulmonary fibrosis patients *** Idiopathic Pulmonary Fibrosis Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A prospective, longitudinal, non-pharmacological, case-controlled study to evaluate longitudinal disease behavior and biomarker data over a 52-week period in idiopathic pulmonary fibrosis patients *** Idiopathic Pulmonary Fibrosis Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i janv-15 mai-16
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT02320721?term=EFC13799&draw=2&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002399-10
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs Not available déc-15 nov-16
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT02585674?term=EFC13470&draw=2&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004533-13
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i mars-15 févr-16
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT02401243?term=GLARGL07496&draw=2&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL Not available
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i nov-04 nov-07
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00174668?term=HMR1964A_3504&draw=2&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical 52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001287-49
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i déc-04 déc-08
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT00174642?term=HMR1964A_3506&draw=2&rank=1
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002036-25
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Combination Therapy of Insulin Glargine and Sitagliptin in Patients With Type 2 Diabetes Not Adequately Controlled by a Previous Treatment With Metformin and Either Insulin Glargine or Sitagliptin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i June-09 sept-11
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Combination Therapy of Insulin Glargine and Sitagliptin in Patients With Type 2 Diabetes Not Adequately Controlled by a Previous Treatment With Metformin and Either Insulin Glargine or Sitagliptin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i
Pharma, Research and development Sanofi Clinical Studies TBD Clinical Combination Therapy of Insulin Glargine and Sitagliptin in Patients With Type 2 Diabetes Not Adequately Controlled by a Previous Treatment With Metformin and Either Insulin Glargine or Sitagliptin *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Eudra CT URL https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Multicenter, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Insuman Comb 25 (Insulin Human) Versus Novolin® 30R Twice Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus Who Are Under Insulin Therapy *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA Sponsor Clinical Registry URLs https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i mai-11 nov-12
Pharma, Research and development Sanofi Clinical Studies TBD Clinical A Multicenter, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Insuman Comb 25 (Insulin Human) Versus Novolin® 30R Twice Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus Who Are Under Insulin Therapy *** Diabetes Mellitus Type 2 Structuré Csv, .SAS, .xpt, .parquet NA ClinTrials Gov URL https://clinicaltrials.gov/ct2/show/NCT01353469?term=EFC12059&draw=2&rank=1

* Generali does not make any representation or warranty as to the (i) access to or availability (at any time) of the dataset listed in the present catalogue nor as to (ii) the accuracy or completeness of such datasets or any data or information contained therein. Nothing contained herein shall be construed as granting or conferring any rights or license in any datasets and information listed in the present catalogue.

Notwithstanding the fact that all information in this catalogue is anonymized, all information contained in this catalogue is confidential and shall not be disclosed to any third party without the prior written consent of Generali.

Without prejudice to the foregoing, any access to the datasets listed in this catalogue is subject to a feasibility analysis on a project by project basis by Generali in particular in light of the (a) applicable license terms (b) applicable rules, regulations and standards determined by any governmental or regulatory authority or by any self-regulatory body, (c) internal policies of Generali and (d) signature of a definitive agreement with Generali laying out the conditions of access and use of any of the listed datasets".

** "Specific conditions of use for the creation of proof of concept or for research purposes:
Orange Business Services retains ownership of the indicators which are made available for the purposes of the Start-up's Project. The Project must be jointly defined and validated by both parties.
These data can be kept and used only for the duration and the exclusive purposes of the Start-up Project and no case for commercial purposes. Thereafter, the used data must be returned to Orange Business Services or destroyed by the start-up.

The free sharing and communication of the results of the Project using Orange Business Service(Flux Vision) indicators are permitted under the condition that they should contain only exploitations of the final results of the Project and provided that they do not contain our statistical indicators in their raw state but only transformed for the needs of the project.
This data may only be used by a limited number of people specifically authorized to access and to use this data. The start-up subscribing to the offer undertakes to inform the relevant persons of these restrictions of use and to ensure that they are strictly respected. The list of persons authorized to access and use the data must be specified in the Order Form.

Orange Business Service must be informed of any public communication of the results of the Project integrating the use of its data and reserves the right to ask to appear or not to appear as a data provider for the Project".

*** "Sanofi does not make any representation or warranty as to the (i) access to or availability of the [dataset] listed in the present catalogue nor as to (ii) the accuracy or completeness of such datasets or any [data or information contained therein]. Nothing contained herein shall be construed as granting or conferring any rights or license in any [datasets and information] listed in the present catalogue.

All information contained in this catalogue is confidential and shall not be disclosed to any third party without the prior written consent of Sanofi.

Without prejudice to the foregoing, any access to the datasets listed in this catalogue is subject to a feasibility analysis on a project by project basis by Sanofi in particular in light of the (a) applicable license terms (b) applicable rules, regulations and standards determined by any governmental or regulatory authority or by any self-regulatory body, (c) internal policies of Sanofi and (d) signature of a definitive agreement with Sanofi laying out the conditions of access and use of any of the listed datasets”.